Loading...
•
Sep 30, 2022
Cullinan Oncology Q3 2022 Earnings Report
Cullinan Oncology reported financial results for Q3 2022 and provided a corporate update.
Key Takeaways
Cullinan Oncology reported cash and investments of approximately $607 million as of September 30, 2022. The company is focused on advancing its pipeline and strategically deploying capital for investment, acceleration, and expansion.
Initiated pivotal study for zipalertinib (CLN-081/TAS6417).
Increased ownership in MICA subsidiary, which holds worldwide rights to CLN-619, from 54% to 92%.
Continued enrollment in CLN-049 and CLN-619 clinical studies with initial clinical data updates on track for mid-2023.
Cash and investments of approximately $607 million as of September 30, 2022.
Cullinan Oncology
Cullinan Oncology
Forward Guidance
Cullinan Oncology remains on track to file IND applications for CLN-617 and CLN-978 in the first half of 2023.